Richard C Deth

US Patent:

6773892, Aug 10, 2004

Filed:

Apr 14, 2000

Appl. No.:

09/550103

Inventors:

Richard C. Deth - Waban MA

Assignee:

Northeastern University - Boston MA

International Classification:

G01N 3353

US Classification:

435 72, 435 721, 435 35, 435 405, 436501, 436503, 436504

Abstract:

Methods for detecting schizophrenia or related neuropsychiatric disorders based on modifications of the contribution of the D receptor to phospholipid methylation levels are described herein. Individuals with schizophrenia or related neuropsychiatric disorders have a deficiency in phospholipid methylation activity compared with normal individuals. Methods for screening therapeutic processes or agents for use in treatment of schizophrenia or related neuropsychiatric disorders are also described.

US Patent:

56862555, Nov 11, 1997

Filed:

May 24, 1995

Appl. No.:

8/449153

Inventors:

Richard C. Deth - Waban MA

International Classification:

G01N 3353

US Classification:

435 721

Abstract:

Methods and compositions for detecting schizophrenia based on modification of the dopamine D. sub. 4 receptor by addition of an adenosyl group to methionine #313 via methionine adenosyltransferase are described herein. Individuals with schizophrenia have a deficiency in methionine adenosyltransferase activity and a lower amount of modified dopamine D. sub. 4 receptor than normal individuals. Methods for screening therapeutic processes, agents and drugs for use in treatment of schizophrenia are also described.

US Patent:

60805498, Jun 27, 2000

Filed:

Apr 8, 1997

Appl. No.:

8/833703

Inventors:

Richard C. Deth - Waban MA

Assignee:

Northeastern University - Boston MA

International Classification:

G01N 33567
G01N 3348

US Classification:

435 721

Abstract:

Methods for detecting schizophrenia or depression based on modifications of the contribution of the D. sub. 4 receptor to phospholipid methylation levels are described herein. Individuals with schizophrenia or depression have a deficiency in phospholipid methylation activity compared with normal individuals. Methods for screening therapeutic processes or agents for use in treatment of schizophrenia or related neuropsychiatric disorders are also described.

US Patent:

57389985, Apr 14, 1998

Filed:

May 24, 1995

Appl. No.:

8/449651

Inventors:

Richard C. Deth - Waban MA

International Classification:

G01N 3353

US Classification:

435 721

Abstract:

Methods and compositions for detecting schizophrenia based on modification of the dopamine D. sub. 4 receptor by addition of an adenosyl group to methionine #313 via methionine adenosyltransferase are described herein. Individuals with schizophrenia have a deficiency in methionine adenosyltransferase activity and a lower amount of modified dopamine D. sub. 4 receptor than normal individuals. Methods for screening therapeutic processes, agents and drugs for use in treatment of schizophrenia are also described.

US Patent:

20190030061, Jan 31, 2019

Filed:

Mar 1, 2017

Appl. No.:

16/081111

Inventors:

- Fort Lauderdale FL, US
Richard Deth - Fort Lauderdale FL, US

Assignee:

NOVA SOUTHEASTERN UNIVERSITY - Fort Lauderdale FL

International Classification:

A61K 31/714
A61K 33/00
A61K 31/519
A61K 31/122
A61K 9/00
A23L 33/15
A23L 33/16

Abstract:

The invention provides cobalamin (vitamin B) nutraceutical compositions and methods for use thereof for improving cognitive function in subjects having disorders of cognitive function such as neurodegenerative disorders, neurodevelopmental disorders, and neuropsychiatric disorders. This improvement in cognitive function is achieved through the ability of the cobalamin (vitamin B) nutraceutical compositions to increase methylation capacity and vitamin Bactivity in the brains of the subjects.